iShares iBoxx $ Inv Grade Corporate Bond ETF vs Koninklijke Philips NV — how do they compare? iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $102.41 (market cap $28.50B), while Koninklijke Philips NV trades at $24.24 (market cap $23.52B). The key difference: iShares iBoxx $ Inv Grade Corporate Bond ETF is the larger of the two by market cap, and Koninklijke Philips NV pays a 4.17% dividend while iShares iBoxx $ Inv Grade Corporate Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares iBoxx $ Inv Grade Corporate Bond ETF for 125 Days and Koninklijke Philips NV for 84 Days on average.
| LQD | PHG | |
|---|---|---|
Market Cap | $28.50B | $23.52B |
Volume | 37,320,110 | 1,635,069 |
Sector | Fixed Income | Health |
52-Week High | $112.91 | $32.91 |
52-Week Low | $101.83 | $23.81 |
Typical Hold Time | 125 Days | 84 Days |
Enterprise Value | — | $29.87B |
Dividend Yield | — | 4.17% |
Signals from Pluang's Aura AI — not financial advice
LQD trades at $102.41 with a slight 0.28% daily gain amid a challenging bond market environment. The ETF shows bearish technical signals with moving averages indicating selling pressure, though oscillators remain neutral. Recent news highlights significant short interest growth of 53.1% in September and concerns about investment-grade corporate bonds as Treasury yields hit multi-decade highs. The fund maintains consistent dividend distributions with recent payouts around $0.44-0.46 per share.
The outlook remains cautious given the bearish technical setup and rising bond yields pressuring corporate debt valuations. Key risks include continued bond market volatility and higher borrowing costs for issuers. Investment opportunities exist for income-focused investors seeking exposure to investment-grade corporate bonds, though near-term price pressure may persist until bond market conditions stabilize.
PHG trades at $24.24, up 0.62% today, amid a bearish technical signal from moving averages. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results pending. Recent financials show a return to profitability in 2025 with net income of $895 million, while cash flow from operations remains positive at $1.17 billion. Key developments include new product launches in healthcare imaging and a $33.7 million ARPA-H award for AI-enabled stroke care.
The outlook is mixed: strong earnings momentum and solid profitability metrics support upside, but technical weakness and a high 'Hold' analyst consensus suggest near-term caution. Risks include competitive pressures and debt levels, though institutional buying activity indicates underlying confidence.
Trailing returns across standard periods
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →